share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

SEC announcement ·  Jun 6 06:17
Summary by Futu AI
Recursion Pharmaceuticals, Inc. (RXRX) reported that Blake Borgeson, a key figure at the company, was granted 13,097 shares of Class A Common Stock on June 3, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Borgeson's direct holdings in the company have increased to a total of 7,200,010 shares of Common Stock.
Recursion Pharmaceuticals, Inc. (RXRX) reported that Blake Borgeson, a key figure at the company, was granted 13,097 shares of Class A Common Stock on June 3, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Borgeson's direct holdings in the company have increased to a total of 7,200,010 shares of Common Stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.